Scheme2.Preparation of 3-alkoxy-5-nitroindazole-derived amines 3-6 and 7-10 designed in the present work:a)for 3, 5:3 3% MeNH 2 /EtOH,R T, 24 h, 90 %y ield;for 4, 6:sat. NH 3 /MeOH, 70 8C( autoclave),3days, 79 and 81 % yields, respectively;b)13 or 14,K 2 CO 3 ,CH 3 CN, reflux, 3days (for 7, 9)o r 7days(for 8, 10), 75-91 %y ield.
Introduction
Americant rypanosomiasis, commonly known as Chagas disease (CD), is one of the most prevalent parasitic neglected tropical diseases (NTD) [1] and am ajor cause of morbiditya nd mortality in many areas of Latin America [2] according to the World Health Organization (WHO). Although the disease has its greatest impact on Latin America, its spread to the eastern hemisphere and first-world countries [3] [4] [5] has converted CD into ag lobalp roblem, [6] infecting more than 10 millionp eople worldwide and more than 25 million are at risk of contracting CD. [7] The protozoanp arasite Trypanosoma cruzi is the causative agent of CD, the most important parasitei nL atin America [8] and the leading cause of premature heart disease. [9] T. cruzi is naturallyt ransmitted by hematophagus insects, is strongly linked to low socioeconomic factors, although other means of transmission include the congenital route, contaminated food and drink, organ transplantation, and bloodt ransfusion. [9] [10] [11] CD can be divided into distinct stages.T he acutes tage is usually relatively mild and often undiagnosed;2 0-30% of infected individuals proceed to the "chronic" stage, sometimes decades later. [12] This phase is characterizedb yc linicalm anifestations, including cardiomyopathy and, more rarely,d amage to the digestive tract (mainly megacolon and megaesophagus) and/or lesionsint he peripheral nervous system. [9] The lack of public policies, the missing interesto ft he pharmaceutical industry,t he long-term nature of CD andi ts complex pathology have resulted in alack of drugs suited for effective treatments, and no vaccineh as been developed. [13] A major example of this is that over ac entury after discovery of the disease by Carlos Chagas in 1909, only two old nitroheterocyclic drugs-nifurtimox (NFX) and benznidazole (BZN) ( Figure 1 )-are currently available. [14] Unfortunately,t he efficacy of these two antiprotozoala gents is not higher than 70 %, being worst during the chronic phase of the disease, [15] not to mention the wide range of adverses ide effects whichm ay lead, in several cases,t os top therapy abruptly. [16, 17] This, cou-Chagas disease, an eglected tropical disease caused by infection with the protozoan parasite Trypanosoma cruzi,i sapotentially life-threatening illness that affects 5-8 million people in Latin America,a nd more than 10 million people worldwide. It is characterized by an acute phase, which is partly resolved by the immune system,b ut then developsa sachronic disease withouta ne ffective treatment. There is an urgent need for new antiprotozoala gents, as the current standardt herapeutic options based on benznidazole andn ifurtimoxa re characterized by limitede fficacy,t oxicity,a nd frequent failures in treat-ment. In vitro and in vivo assays were used to identify some new low-cost 5-nitroindazoles as ap otentiala ntichagasic therapeutic alternative. Compound 16 (3-benzyloxy-5-nitro-1-vinyl-1H-indazole) showedi mproved efficiency and lower toxicity than benznidazole in both in vitro and in vivo experiments, and its trypanocidal activity seems to be relatedt oi ts effect at the mitochondrial level. Therefore, compound 16 is ap romising candidate for the development of an ew anti-Chagas agent,a nd further preclinical evaluation should be considered.
pled with that both drugs are prodrugs that requiret ob eactivated by the same mitochondrial nitroreductase [18, 19] -a phenomenon with potential to result in cross-resistance-makes the developmento fs afer and more widely effective antiprotozoal agentsamajor priority.B riefly,t he ideal drug defined by the Ta rget Product Profile (TPP) should present better safety profile and an efficacy at least equal to BZN. [20] Moreover,t he search for new targetsf or chemotherapy is am ajor challenge. Amongt hem, the parasite antioxidant system has attracted attention duetoi ts uniquenessint he trypanosomatids.
With the aim of obtaining novel compoundsa sp otential agents against CD, we have studied in the last years the antiprotozoal properties of many 5-nitroindazole derivatives, prepared by simple andi nexpensive synthetic routes. In relation to the present work, we can mention the antichagasic activity reportedf or some 3-alkoxy-1-alkyl-5-nitro-1H-indazoles. The initially studied compounds were tertiary amines containing w-(dialkylamino)alkylo r-oxaalkylc hains at position 1o ft he heterocyclic ring (Figure 1, compounds 1) ; [21] [22] [23] [24] recently,w eh ave also reported the trypanosomicidal properties of some primary and secondary 5-(indazol-1-yl)-3-oxapentylamines ( Figure 1 , compounds 2)a nd related bis[5-(indazol-1-yl)-3-oxapentyl]amines. [25] To explore the tolerance to structural changes of the mentioned 1,3-disubstituted 5-nitroindazole system,w ed escribe here the synthesis, cytotoxicity,i nv itro and in vivo trypanocidal activity and the possible mechanismso fa ction-the excreted metabolites,the mitochondrial membrane potential and the inhibition of iron superoxide dismutase (Fe-SOD)-of some new 5-nitroindazole-derived primary (4, 6) , secondary (3, 5, 8, 10) a nd tertiary (7, 9) a mines supporting as ubstituted ethyl chain at position 1o ft he heterocyclic ring ( Figure 2) . The required synthetic intermediates (13, 14) a sw ell as some reac-tion byproducts (15, 16) ( Scheme 1) were also studied. The compounds were tested in epimastigote, amastigote and trypomastigote forms in three different T. cruzi strains( Arequipa, SN3 and Tulahuen), the cytotoxicity was determined in Vero cells, and the in vivo trypanocidal activity was evaluated in both acute and chronic phases.
Results

Chemistry
The desired 3-alkoxy-1-(2-aminoethyl)indazoles 3-10 ( Figure 2 ) were obtained from 2-bromoethyl derivatives 13, 14 which were, in turn, prepared (Scheme 1) by N-1 alkylation of 3-alkoxyindazoles 11, 12 with 1,2-dibromoethane;a lthough an excess of the latter was used in order to minimize the formation of bisindazole derivatives, [26] 18 were obtained as byproducts in these reactions. 3-Alkoxy-1vinylindazoles 15, 16,a rising from 2-bromoethyl derivatives 13, 14 through hydrogen bromide elimination, could also be isolated in low yield from these processes. From ap reparative point of view,1 -vinylindazoles 15, 16 could also be obtained in quantitative yield from 13, 14 by dehydrobromination with K 2 CO 3 /1-propanolatr eflux.
Treatmento f2 -bromoethyl derivatives 13, 14 with methylamine or ammonia afforded N-methyl-2-(indazol-1-yl)ethylamines 3, 5 or the corresponding primary amines 4, 6.F inally, alkylation of amines 3-6 with the required bromides 13, 14 yielded the desired tertiary (7, 9) a nd secondary (8, 10)i ndazole-derived amines (Scheme 2).
Biology
In vitro trypanocidalevaluation
The extracellular epimastigote-like form is the most commonly used because of its simple culture and maintenance in vitro. However,t estsa gainst the developedf orms in vertebrate hosts, bloodstream trypomastigotes (BTs) and intracellular amastigote-like forms (responsiblef or the chronic phase of CD) are more appropriate. [27] On the one hand, the in vitro trypanocidal activity of compounds 3-10, 13-16 and the reference drug BZN wase valuated on epimastigote forms with the objective of obtaining the half-maximali nhibitory concentrations (IC 50 values;T able 1). On the other hand, the cytotoxicity was tested using Vero cells to determine the toxicityi nm ammalian cells (Table 1 ) and the selectivity index (SI = IC 50 Vero cells/IC 50 extra-and intracellular forms;T able 2). Interestingly,B ZN was substantially more toxic than the tested compounds:2 3.2 mm in contrastt ov alues ranged from 34.9 to 493.9 mm,r espectively.T he compounds with IC 50 values lower than 50 mm and SI highert han 10 were then evaluated in amastigotea nd trypomastigote forms (Tables1and 2). Compounds 3 and 16 showedt he best trypanocidal activities, which were even better than those of BZNi n epimastigote, amastigote and trypomastigote forms in the three T. cruzi strains.
In vivo trypanocidal evaluation in BALB/c mice
In vivo tests were performed for the evaluation of:a )Parasitemia levels by counting BTsa sa ni ndicator of the effectiveness of acute phase treatment;b )Parasitemia reactivation in the chronic phase by counting BTsa fter immunosuppression (IS) as an indicator of the effectiveness in both the acute and chronic phase treatments;c )Infected target organs in the chronic phase by PCR after IS as an indicator of the effectiveness in both the acute and chronic phase treatments;d )Levels of immunoglobulin G( IgG) by enzyme-linked immunosorbent assay (ELISA); e) Splenomegaly as indicatorso fi mmune response in both the acute and chronic phases;f )Serum parameters by biochemical measurements as an indicator of metabolic disturbancesassociated with the treatment.
The treatment was performed from the 10 th to the 14 th day post-infection (dpi)f or the acute phase and from the 75 th to the 79 th dpi (it is established that the animalse nteredt he chronic phase, in whichthere are no parasites remaining in the bloodstream) for the chronic phase. Oral therapy leads to [b] Ama [c] Try [d] Epi [b] Ama [c] Try [d] Epi [b] Ama [ better patient compliance and has al ow cost (criticala spects of human treatment in developingc ountries). [28] Moreover,o ral administration is the preferred route fort he treatment of parasitic diseases. First, parasitemia levels were determined in the different groups of mice in the acutep hase ( Figure 3 ). Nonsignificant differences wereo bserved in mice treated with compound 3 with respectt ot he untreated mice, but ad ecreasei np arasitemia was observed in mice treated with compound 16,w hich exhibitede ven betteri nv ivo trypanocidal activity than BZN. The trypanocidal activity of compound 16 was evident from the beginning of the treatment, and the parasitemia was undetected 11 and 9d ays before (38 th dpi)w ith respect to the control and BZN-treated mice, respectively.A lternatively,t he peak of parasitemia (23 rd dpi)i nm ice treated with compound 16 caused ad ecrease of % 70 %w ith respect to the control mice.
Second, to evaluate the effectiveness of thet reatment and the disease extent in the chronic phase, the parasitemia reactivation was determined after IS until the 120 th dpi (late chronic phase, when the amastigote form is nested inside target organs/tissues) with the objective of reactivating the parasitemia under the control of the immunological system of the mice. The percentages of reactivation of parasitemia after IS ( Figure 4 ) were proportionalt ot he survival rate of the parasites in the acute phase treatment, and the effectiveness of treatments in the chronic phase were shown (as confirmed below with the results of infected organs). As ignificant de-crease in the reactivation of parasitemia was observed in both phases for mice treated with compound 16 (30 %f or acute phase and 35 %f or chronic phase), which were higher than Table 2 . Selectivity index for compounds 3-10 and 13-16 on extra-and intracellularf orms of T. cruzi strains.
CompdS electivity index [a]
ArequipaSN3 Tulahuen Epi [b] Ama [c] Try [d] Epi [b] Ama [c] Try [d] Epi [b] Ama [c] Try [d] BZN1 those of the reference drug BZN (75 and 51 %, respectively). In contrast, theser esults showed that the effectiveness of compound 3 was better in chronic than in acute phase (as mentioned below). Finally,t he presence of parasites in the defined as target organs/tissues (positive for control groups:a dipose, bone marrow,b rain, esophagus, heart, lung, muscle, spleen and stomach)w as determined by PCR after necropsy (127 th dpi)t o evaluate the curative effect of these nitroindazoles as as econd technique of confirmation of cure ( Figure 5 ). BZN-treated mice were shown to have 33 and 55 %p arasitefree organs/tissues in the acuteand chronic phases,respective-ly.I nterestingly,anotable in vivo trypanocidala ctivity was observedf or mice treatedw ith compound 16,w ith 67 %o fp arasite-free organs/tissues for mice treated in the acute and chronic phases.
It is well known that IgG levels (anti-T. cruzi IgG) are linked with the parasite load [29] such that the detection of total IgG reflects the infection rates, and verifiest he effectiveness ascribed to the tested nitroindazoles together with the innate protection of mice. Because of that, aiming at evaluating the immune status of the mice during infection, the titer of anti-T. cruzi IgG was determined by ELISA ( Figure 6 ), and the isolated Fe-SODe nzymes uch as antigen. [30] The titer of anti-T. cruzi IgG decreased for mice treated with BZN and compound 16 in all analyzed samples except for those of 81 st dpi in the chronic www.chemmedchem.org phase, which is logical, as its samples from mice are only from 2days after treatment andhave previously suffered an untreated acute phase.
Nonsignificant differences were observed for mice treated with compound 3.I nc ontrast, an otable decrease in the IgG levels occurred in mice treated with compound 16,s uggesting af ormidable in vivo trypanocidal activity consistentw ith the previousstudies.
Splenomegaly is another feature linked to the parasite load because the spleen is an organ that is implicated in immune defensea gainst infection.S plenomegaly occursi ne xperimentally infected mice in which the spleen of chronic mice is approximately twice the mass of those from uninfected mice. [31] Accordingly,w eightp ercentage of spleens was determined from different groups of mice ( Figure 7 ). According to that mentioned above,u ninfected mice showed aw eightp ercentage of spleeno f0 .28 %, and untreated (control) mice exhibited valuest hat were twicet he value corresponding to uninfected mice:0 .56 and 0.59 %i nt he acute and chronic phase experiments, respectively.
Because infection-induced splenomegaly is linked to the parasite load, [31] BZN-treated mice showed ad ecrease in splenomegaly,e ven at subcurative doses and in the absence of parasitological cure. Interestingly,m icet reated with compound 16 showed aw eight percentage of 0.30 %f or mice treated in the acute phase and 0.42 %f or mice treated in chronic phase, which means ad ecrease in splenomegaly of 93 and 55 %c ompared with untreated mice, respectively.I ts houldb er emarked that the highers plenomegaly observed in the mice treated in the chronic phase shouldn ot be related to al ower activity, but rather to the fact that thesem ice suffered an acute phase without treatment, i.e.,highlevels of parasitemia.
Finally,b iochemical clinicalp arameters were measured to confirm the possible metabolic abnormalities associatedw ith treatment ( Table 3 ). Most of the biochemical parameters for the mice treatedw ith the two nitroindazoles were not altered more than for mice treated with BZN after administration, and % 50 %r eturnedt on ormal levels on the day of mice necropsy. Table 3 . Biochemical clinical parameters measured at different experimental situations and daya post-infection (dpi)i ng roups of Balb/c mice infected with T. cruzi.
Kidney marker profile Heartmarkerp rofile
Liver marker profile Urea ALT/GPT,a lanine aminotransferase. dpi = day post-infection.K ey: = ,v ariation no largert han 10 %; + ,u pt o1 0% increase over the range; ++,u pto 20 %i ncreaseo ver the range; +++, up to 30 %i ncrease over the range; ++++,m ore than 40 %i ncrease over the range; À,u pt o1 0% decrease over the range; ÀÀ,u pt o2 0% decrease over the range; ÀÀÀ,upt o3 0% decrease over the range; ÀÀÀÀ,more than4 0% decrease over the range.
Studies of the action mechanism
Metabolite excretion study
It is well known that T. cruzi is unable to totally degrade glucose to CO 2 in the presenceo foxygen, ande xcretes into the mediumaconsiderable portion of the hexoses keleton as incompletely oxidized final productsi nt he form of fermented metabolites (so-called aerobic fermentation): pyruvate, acetate, succinate, l-alanine, d-lactate, and ethanol. [32] [33] [34] The 1 HNMR spectra of culture media werer egistered in order to obtaini nformationr egarding the effects of compounds 3 and 16 on the glucose metabolism of T. cruzi (spectra not shown). The final excretionsw ere qualitatively and quantitatively analyzed and compared with those found for untreated (control) T. cruzi epimastigotes (Figure8). Compound 3 showed no significant disturbanceso ng lucose metabolism; however,t he excretion of all metabolites was increased in epimastigotes treated with compound 16,e speciallys uccinate (113 %). It is interesting to mention that an increase in succinate excretion indicates catabolic alterations that could be related to am itochondrial dysfunction. [35] Effects on mitochondrial membrane potential and on DNA and RNA levels in T. cruzi
In normal cells, to sustain the electrochemical potential and functiono fm itochondria,a na ctive pumping of H + is produced during the electron transport chain. It is well-knownt hat mitochondriap lay an imperative role in cell death, [36] and disturbances in the mitochondrial membrane potential lead to ad ecrease in ATPp roduction and ar eduction in DNA and RNA levels, causing necrosis and/ora poptosis. [37] Therefore, the fluorescencei ntensity of rhoda-mine 123 (Rho 123) and acridine orange (AO) was quantified by cytometry flow to evaluatea nd relate the effect of compounds 3 and 16 on the membrane potentiala nd on the DNA and RNA levels,respectively.
We suggestt hat the trypanocidal activities of compound 3 and 16 could be partially associated with its mitochondrial effect (Figure 9 ), although the parasites treated with compounds 3 and 16 showedl ower depolarizations in the mitochondrial membrane than BZN (35.6 and 23.5 %, respectively).
Nonspecific nucleic acid degradation is af eature intimately connected to cell necrosis, [38] accordingly,D NA and RNA levels were determined ( Figure 10 Enzymes are one of the most studied therapeutic targets, and the Fe-SOD is at rypanosomatid exclusive enzyme and absent in other eukaryotic cells. [39, 40] It presents biochemical and structural differencesw ith respectt oi ts human homologue Cu/Zn-SOD enzyme. The crucial role performed by this enzyme is the elimination of reactiveo xygen species( ROS), allowing trypanosomatidst op rotect themselves from the damage produced by oxidative stress. [41, 42] Therefore, the inhibitory effects of compounds 3 and 16 on thesee nzymes were determined using the method described by Beyer and Fridovich [43] (Figure 11 ).
Higher inhibitions were observed on the parasite enzyme than on the human SOD for both compounds.S ignificant inhibition values were found for the Fe-SOD enzymef or compound 3, with an IC 50 value of 5.3 mm.T herefore, we suggest that this inhibitory effect on the Fe-SOD enzymeb ec onsidered one of the causes of the in vitro trypanocidal activity of compound 3. For compound 16,t he IC 50 value (23.4 mm)i st oo high to attribute the trypanocidal effect on the inhibition of the parasite enzyme.
Discussion
At present, the genetic diversity of T. cruzi is widely recognized, and the parasite is classified into seven discretet yping units (DTUs), with differente volutionary relationships, ecological and epidemiological associations, tropism, pathogenesis, geno-types, phenotypesa nd drug resistance. [43] Accordingly,t hree different T. cruzi strains (TcI, TcV, and Tc VI), with different tropisms, hosts and locations, were used to evaluatet he synthesized compounds, to determine the compounds with ag ood performance, and to select those compounds that avoid the natural resistance of the three strains.M oreover,a ccordingt o some authors, it must be kept in mind that potentiala ntichagasic agents have to meet certain in vitro criteria:t he IC 50 value must not exceed 10 mm,a nd the SI must be 10-fold higher. [44] We tested initially against epimastigoteso fthet hree strainso fT. cruzi all new 5-nitroindazole derivatives (3) (4) (5) (6) (7) (8) (9) (10) (13) (14) (15) (16) , and only the few compounds with IC 50 < 50 mm and SI > 10 were evaluated against the corresponding amastigotes and trypomastigotes. Considering only the complete results obtained against epimastigotes, we have not been able to find ac lear structure-activity relationship for these compounds. Amonga mines, 3-methoxy-N-methyl derivative 3 was much more active and selectivet han the remaining compounds against epimastigoteso ft he different studied strains( IC 50 < 2.9 mm;S I> 158), and this high activity was also displayed against the corresponding amastigotes( IC 50 < 2.2 mm;S I> 208) and trypomastigotes (IC 50 < 1.8 mm;S I> 254). Compound 3 was also more efficient than the relatedi ndazole-derived amines 1, 2 (Figure 1 ), previously studied against SN3 [25] and CL Brener [21, 23, 24] strainso ft he parasite. On the other hand, 3benzyloxy-1-vinylindazole 16,areactionb yproduct which was not included in our initial design ( Figure 2 ), showeda lso good trypanocidal properties and selectivities (IC 50 = 1.5-12.4 mm; SI = 21-178). Thus, the commented 5-nitroindazoles 3 and 16, showingb etter trypanocidal activities than the reference drug BZN and good selectivities in the three forms of the three T. cruzi strains, were selectedf or furtherinv ivo evaluation.
The in vivo assays on BALB/c mice wereo nly performed with T. cruzi Arequipa strain with the object to limit as much as possible animal testing, and as there were no significant differences between the performances of the selected compounds for the other evaluateds trains.M oreover,a nd because of the performance of drugs duringt he acute and chronic phases is not as effective as it should be, [45] the impact of these 5-nitroindazole derivatives was evaluated by treating mice in each phase.
The treatment was 20 mg kg À1 per day for five consecutive days, that is, subcurative doses for the BZN, to evaluatewhether the compounds 3 and 16 demonstrated higherinvivo effectivenesst han the reference drug. Noticeably,n one of the treated mice died duringt he treatment or lost more than 10 % body mass. The fact that mice treated with compound 16 lack of toxicity,t ogetherw ith this treatment guideline significantly decreased parasitemia (especially during the days of treatment), higherd oses and/or an ew treatmentg uideline based on pharmacokinetic studies could be administered to achieve at otal cure. We must highlight that inadequate pharmacokinetics between the compounds and the locations of the parasites in the tissues during the chronic phase of infection are related to different effectiveness levelsi nt he acute and chronic phases. [46] Furthermore,t he formidable in vivo trypanocidala ctivity of compound 16 was confirmed with two techniques of cure confirmation [47] in both acute and chronic phase treatments. First, IS was performedb ecause of the fact that apparently cured immunocompromised individuals present clinically aggressive reactivation of the parasitemia. Second, the PCR technique was carried out to determine the presence or absence of parasites in the target organs. The mice with no parasitemia after IS and negative PCR results are considered cured. [48] As expected, mice treated with compound 16 in the acutep hase exhibited the lowest reactivation after IS, and the presenceo fp arasites by PCR was negative for most of the analyzed organs. Interestingly,m ice treated with compound 16 in the chronic phase showedsimilar results, also being the compound that obtained the best results.
It should be noted that assessment of clinicalc ure is debatable because of the lack of ar eliable test to ensure parasite elimination. [49] The PCR techniquet oi dentify cure is an intricate question, and its main utility is to verify the failure of clinical cure because even consistently negative results( for which PCR is ablet od etect as ingle parasite in 5mLo fb lood) are insufficient to ratify the absence of parasites in tissues. [50, 51] In this regard, Ta qMan technology has improved the detection by specific PCR (using sequences of constant regionsa nd variables of minicircles of kinetoplast DNA, fluorogenic probesa nd real-timea mplification reaction), and it is quite useful to assess the parasitic load in earlier and later-treated chronic patients and for the coming establishmento fasuitable criterion for the curing of patientss ubmitted to therapy. [52] Concerning animal testing, IS is the formula employed to prove cure, [53] and we assess the establishment of cure using ad ouble confirmation based on IS and PCR. At present,s ensitive bioluminescence imaging modelt echniques are used to demonstrate cure. [31] However,w ec an provide evidence of curation (or a considerable decrease in the parasite load) found on the results of three independent samples by IS and PCR.
According to the mechanism of action,i ti sw ell-known that the observed accumulationo fs uccinate, pyruvate and malate could be the result of am itochondrial dysfunction [35] by causing ab lockade of the glycolytic pathway.M oreover,t he observed increase in the excretions of glycerol and ethanol are the result of that the parasite used glycosomal and cytoplasmic alternative catabolic routes, respectively,i ne nergy deficient conditions, such as mitochondrial dysfunction that was subsequently analyzed. [33] In addition, ad ecrease in the mitochondrial membrane potential could produce an imbalance in the NADH/NAD + and ATP/ADP ratios, [33] which could be the cause of the observedd ecrease in DNA and RNA levels of the parasite. Thus, we suggest that the trypanocidal activity of compound 16 could be related to its mitochondrial effect.
Conclusions
The trypanocidal properties of new 5-nitroindazole derivatives were evaluated both in vitro and in vivo. Compound 16 exhibited highere fficiency and lower toxicity than the reference drug BZN, in both the acute and chronic phase treatments, as showedP CR and IS assays. To achieve at otal cure and due to the lack of toxicity at the dose tested, compound 16 will be evaluateda th igherd oses and/orm odifying the treatment schedulef or ab etter exposure. Action mechanism studies were performed in parallel, which showed that its antiprotozoal activity could be related to am itochondrial effect. Inhibition studies will be performed at the level of both trypanothione reductase and respiratory chain, as these are possible targets.C onsequently,w ep resent compound 16 as ap romising, simple and low-cost therapeutic alternative for the development of an ew antiprotozoal agent against CD to be implemented in af urther step within the preclinicalp hase. To simplify the description of the NMR spectra, bis(indazolylethyl)amines have been numbered as simple compounds. Electron impact (EI) and electrospray (ES + )m ass spectra were obtained on aH ewlett Packard 5973 MSD (70 eV) and on aH ewlett-Packard 1100 MSD spectrometer,r espectively.D C-Alufolien silica gel 60 PF 254 (Merck, layer thickness 0.2 mm) was used for TLC, and silica gel 60 (Merck, particle size 0.040-0.063 mm) for flash column chromatography.S olvents and reagents were obtained from different commercial sources and used without further purification. Microanalyses were performed on aH eraeus CHN-O-RAPID analyzer and were within AE 0.3 %ofthe theoretical values.
Experimental Section
Preparation of 3-alkoxy-1-(2-bromoethyl)-5-nitro-1H-indazoles (13, 14) and related compounds (15) (16) (17) (18) :Am ixture of the corresponding 3-alkoxyindazole (11, 12) [26] (24.0 mmol), 1,2-dibromoethane (22.54 g, 120.0 mmol) and potassium carbonate (3.73 g, 27.0 mmol) in acetone (300 mL) was held at reflux overnight. The solvent was then evaporated and the residue extracted with chloroform (4 100 mL). The organic phase was concentrated and applied to the top of af lash chromatography column;e lution with chloroform afforded the corresponding 1-vinyl derivatives (15, 16) and then the required 1-(2-bromoethyl)indazoles (13, 14) ; further elution with chloroform/acetone mixtures (50:1 to 30:1) afforded the corresponding 1,1'-ethylenebis(3-alkoxyindazoles) (17, 18) .
3-Alkoxy-1-vinylindazoles 15, 16 could also be prepared alternatively as follows:amixture of the corresponding 1-(2-bromoethyl)indazole (13, 14)( 4.0 mmol) and potassium carbonate (1.00 g, 7.2 mmol) in 1-propanol (50 mL) was held at reflux for 3h.T he solvent was then evaporated to dryness and the solid residue extracted with chloroform (4 25 mL). Evaporation of the extraction solvent afforded pure (TLC, 1 HNMR) 1-vinylindazoles 15, 16. (15, 16) w ere extracted with diethyl ether (3 100 mL). The acid so-lution was then basified with an excess of solid potassium carbonate and evaporated to dryness;e xtraction of the solid residue with a2 0:1c hloroform/methanol mixture (4 50 mL) followed by evaporation of the solvent afforded free amines 3 and 5,w hich were converted into the corresponding hydrochlorides by treatment with 36 %a queous hydrochloric acid (1 mL) in ethanol (20 mL The mixture was evaporate to dryness and the obtained solid triturated with chloroform (20 mL);t he insoluble material was recovered by filtration and washed with chloroform (3 5mL) and ethanol (2 5mL) to affordthe corresponding primary amine hydrobromide (4 or 6·HBr). If desired, additional amount of primary amines (4, 6) , together with the corresponding 1-vinylindazoles (15, 16) and secondary amines (8, 10)a lso produced in the reaction, could be obtained as follows:a fter separation and washing of the corresponding primary amine hydrobromide, the combined organic filtrate was mixed with 10 %a queous potassium carbonate and evaporated to dryness. The resulting solid was extracted with chloroform/methanol (10:1) mixture (ca. 100 mL) and the solution evaporated to dryness and applied to the top of af lash chromatography column;e lution with chloroform afforded the corresponding 1-vinylindazoles (15, 16) , and further elution with chloroform/ethanol mixtures (30:1 to 5:1) afforded secondary amines (8, 10) f ollowed by primary amines (4, 6) ; the latter were converted into the corresponding hydrobromides by treatment with hydrobromic acid in ethanol. (13, 14) (2.2 mmol) and potassium carbonate (0.69 g, 5.0 mmol) in acetonitrile (100 mL) was held at reflux for 3days (for 7, 9)o rf or 7days (for 8, 10). The solvent was then evaporated and the residue extracted with chloroform (4 50 mL). The organic phase was concentrated and applied to the top of af lash chromatography column which was eluted first with chloroform to afford the corresponding 1-vinyl derivatives (15, 16) a nd the excess of 2-bromoethyl derivative (13, 14) , and then with chloroform/ethanol (50:1 to 20:1) (for 8, 10)o rc hloroform/acetone mixtures (50:1 to 5:1) (for 7, 9)t oy ield the desired amines. The latter were converted into the corresponding hydrochlorides by treatment with 36 % aqueous hydrochloric acid (1 mL) in ethanol (20 mL) followed by evaporation to dryness. Hydrochlorides of amines 7, 8,a nd 10 were recrystallized from an appropriate solvent;c rude 9·HCl was triturated with acetone to afford pure salt as an amorphous solid. 
Biology
Parasite strain culture:Three different T. cruzi strains were evaluated in this work: T. cruzi SN3 strain (IRHOD/CO/2008/SN3, DTU I) isolated from domestic Rhodnius prolixus from Guajira, Colombia; [54] T. cruzi Arequipa strain (MHOM/Pe/2011/Arequipa, DTU V) isolated from ah uman from Arequipa, Peru;a nd T. cruzi Tulahuen strain (TINF/CH/1956/Tulahuen, DTU VI) isolated from Tulahuen, Chile. Epimastigote culture forms were grown at 28 8Ci nR PMI (Gibco) with 10 %( v/v)f etal bovine serum (heat-inactivated), 0.5 %( w/v) trypticase (BBL) and 0.03 m hemin. [55] In vitro activity assays;epimastigote forms: T. cruzi epimastigotes (strains SN3, Arequipa and Tulahuen) were collected in the exponential growth phase by centrifugation at 400 g for 10 min. The compounds to be tested were dissolved in DMSO at ac oncentration of 0.01 %( v/v)a nd assayed as nontoxic or without inhibitory effects on parasite growth. Trypanocidal activity was determined in our laboratory using ap reviously described method [56] with some modifications. Assays were performed in microtiter plates (96-well plates) at 5 10 5 parasites per mL, and after addition of the compounds at dosages of 100 to 0.1 mm and cultured in 200 mLp er well volumes at 28 8C. Growth controls and BZN were also included. After a4 8h incubation, 20 mL( 0.125 mg mL À1 )o fr esazurin sodium salt (Sigma-Aldrich) was added, and the plates were incubated for af urther 24 h. Finally,5mL( 10 % w/v)o fs odium dodecyl sulfate (SDS) was added, and after 10 min, the trypanocidal activity of the compounds on the plates was assessed by absorbance measurements (Sunrise, TECAN) at 570 and 600 nm. [57] The trypanocidal effect was determined using GraphPad Prism and is expressed as the IC 50 ,i .e.,t he concentration required to result in 50 %i nhibition. Each drug concentration was tested in triplicate in three separate determinations.
Vero cells culture and cytotoxicity tests:V ero cells (EACC number 84113001) from monkey kidney were grown in humidified 95 %a ir, 5% CO 2 atmosphere at 37 8Ci nR PMI (Gibco)w ith 10 %( v/v)f etal bovine serum (heat-inactivated). [58] Vero cells were collected first by trypsinization and then by centrifugation at 400 g for 10 min. The compounds to be tested were dissolved as mentioned above. Cytotoxicity against Vero cells was assessed using microtiter plates (96-well plates) at 1.25 10 4 cells per mL, and after addition of the compounds at dosages of 2000 to 1 mm and cultured in 200 mLp er well volumes in RPMI with 1% (v/v)f etal bovine serum (heat-inactivated). Growth controls and BZN were also included. After a4 8h incubation, the same procedure as described to determine the trypanocidal activity was followed.
Transformation of epimastigotes to metacyclic forms: T. cruzi strains SN3, Arequipa and Tulahuen were grown as epimastigote forms at 28 8C. [59] Metacyclic trypomastigotes (aged epimastigote cultures) were induced by culturing as even-day-old culture of epimastigote forms in Grace's Insect Medium (Gibco)w ith 10 %( v/v) fetal bovine serum (heat-inactivated) at 28 8Cf or 7days. [60] The parasites were then harvested by centrifugation at 400 g for 10 min and incubated at 5 10 8 parasites per mL in TAUm edium (190 mm NaCl, 17 mm KCl, 2mm MgCl 2 ,2 m m CaCl 2 ,8 m m phosphate buffer,p H6.0) for 2h at 28 8C. Thereafter,t he parasites were incubated at 5 10 6 parasites per mL in TAU3AAG medium (TAU supplemented with 10 mml -proline, 50 mml -sodium glutamate, 2mml -sodium aspartate and 10 mmd -glucose) for 4days at 28 8C. [61] Subsequently,t his metacyclic trypomastigotes were used to infect Vero cells in humidified 95 %a ir,5%C O 2 atmosphere at 37 8Ci nR PMI (Gibco)w ith 10 %( v/v)f etal bovine serum (heat-inactivated) for 5t o7days. [62] Finally,t he culture-derived trypomastigotes were collected by centrifugation at 3000 g for 5min and used to infect BALB/c albino mice.
In vitro activity assays;a mastigote forms:V ero cells (EACC number 84113001) from monkey kidney were grown in humidified 95 %a ir,5%C O 2 atmosphere at 37 8Ci nR PMI (Gibco)w ith 10 % (v/v)f etal bovine serum (heat-inactivated) [58] and were collected first by trypsinization and then by centrifugation at 400 g for 10 min. Assays were performed in microtiter plates (24-well plates) at 1 10 4 Vero cells per well with rounded coverslips on the bottom;2 4hlater the cells were infected with culture-derived trypomastigotes of T. cruzi (strains SN3, Arequipa and Tulahuen) at a multiplicity of infection (MOI) ratio of 1:10 during 24 h. Non-phagocyted parasites were removed by washing, and after addition of the compounds at dosages of 50 to 0.1 mm,c ultured in 500 mLp er well volumes in RPMI with 1% (v/v)f etal bovine serum (heat-inactivated) in ah umidified 95 %a ir,5 %C O 2 atmosphere at 37 8C. Growth controls and BZN were also included. After a7 2h incubation, the trypanocidal effect was assessed based on the number of amastigotes in treated and untreated cultures in methanol-fixed and Giemsa-stained preparations. The number of amastigotes was established by analyzing 500 host cells distributed in randomly chosen microscopic fields. The trypanocidal effect was determined using GraphPad Prism and it is expressed as the IC 50 ,i .e.,t he concentration required to result in 50 %i nhibition. Each drug concentration was tested in triplicate in three separate determinations.
In vitro activity assays;t rypomastigote forms: T. cruzi blood trypomastigotes (strains SN3, Arequipa and Tulahuen) were obtained by cardiac puncture from BALB/c albino mice during the parasitemia peak after infection and diluted in RPMI (Gibco)w ith 10 %( v/ v)f etal bovine serum (heat-inactivated). Trypanocidal activity was determined in our laboratory according to ad escribed method [63] with certain modifications. Assays were performed in microtiter plates (96-well plates) at 2 10 6 parasites per mL, and after addition of the compounds at dosages of 50 to 0.1 mm,c ultured in 200 mLp er well volumes in humidified 95 %a ir,5 %C O 2 atmosphere at 37 8C. Growth controls and BZN were also included. After a2 4h incubation, 20 mL( 0.125 mg mL À1 )o fr esazurin sodium salt (Sigma-Aldrich) was added, and the plates were incubated for 4h. Finally,the same procedure as described to determine the trypanocidal activity was followed. Mice infection and treatment:G roups of three mice were infected via intraperitoneal inoculation with 5 10 5 BTso fT. cruzi Arequipa strain (obtained from previously infected mice with metacyclic trypomastigotes) in 0.2 mL phosphate-buffered saline (PBS). The mice were divided, in acute and chronic phases, as follows:0 ,n egative control group (uninfected and untreated);I ,p ositive control group (infected and untreated);I I, BZN group (infected and treated with BZN);I II, study group (infected and treated with the compounds under study). BZN and the compounds under study were prepared at 2mgmL À1 in an aqueous suspension vehicle containing 5% (v/ v)D MSO and 0.5 %( w/v)h ydroxypropyl methylcellulose. [53] Drugs were administered by the oral route ( % 200 mL) once daily for five consecutive days, and vehicle only was administered in the negative and positive control groups. Therefore, doses of 20 mg kg À1 per day were administered for five consecutive days. Administration of the tested compounds was initiated on the 10 th day postinfection (once the infection was confirmed) in mice treated in acute phase and on the 75 th day post-infection (it is established that the animals had entered the chronic phase of the experiment) in the mice treated in the chronic phase.
In vivo trypanocidal activity assays
Parasitemia levels in the acute phase treatment:P eripheral blood from each mouse treated in acute phase was obtained from the mandibular vein (5 mLs amples) and diluted 1:100 in PBS. The number of BTs( parasitemia levels) was quantified every two or three days from 7 th day post-infection until the day parasitemia was not detected. This counting was performed using aN eubauer chamber,a nd the number of BTsw as expressed as parasites per mL. [47] Cyclophosphamide-induced IS:A fter 100 th day post-infection, the groups of mice treated in the acute and chronic phases with significantly decreased parasitemia levels and established to be in the chronic phase of the experiment, regardless of the treatment and undetectable by fresh blood microscopy examination, were immunosuppressed with cyclophosphamide monohydrate (ISOPAC)a s follows:o ne intraperitoneal injection every four days with ad ose of 200 mg kg À1 ,f or am aximum of three doses. [53] The efficacy of such an IS procedure for assessing cryptic infection was verified by the high parasitemia in chronically untreated mice. Within one week after the last cyclophosphamide monohydrate injection, parasitemia was evaluated according the procedure described for par- ChemMedChem 2018 ChemMedChem , 13,2104 ChemMedChem -2118 www.chemmedchem.org asitemia levels in acute phase to quantify the presence or absence of BTsa sthe reactivation rate.
Organs DNA extraction, PCR and electrophoresis:A fter cyclophosphamide-induced IS, mice were bled out under gaseous anesthesia (CO 2 )v ia heart puncture, and blood was collected. Our previous in vivo studies using the T. cruzi Arequipa strain revealed its tropism for the following organs:a dipose tissue, bone marrow, brain, esophagus, heart, lung, muscle, spleen and stomach. Therefore, these nine organs were harvested and immediately perfused with pre-warmed PBS to avoid contamination of the tissue with BTs. [64] In addition, spleen was weighed to evaluate inflammation of this organ in the different groups of mice. Finally,t he target organs were thawed and ground up using aP otter-Elvehjem, and DNA extraction was performed using Wizard Genomic DNA Purification Kit (Promega). [47] PCR was performed based on the published sequence of the enzyme SOD T. cruzi CL Brenner (GenBank accession No. XM_ 808937) using two primers designed in our laboratory that allow the detection of T. cruzi DNA in different biological samples. These primers amplify af ragment belonging to SOD gene bo fT. cruzi consisting of approximately 300 base pairs (bp). The amplifications were performed using aT hermal Cycler TM MyCycler thermal cycler (Bio-Rad) with the following reaction mixture:1 mLo fD MSO, 200 nm iSODd, 200 nm iSODr,1 0mm Tris·HCl (pH 9.0), 1.5 mm MgCl 2 ,5 0mm KCl, 0.01 %g elatin, 0.1 %T riton X-100, 100 mm of each dNTP,0 .5 Uo fT aq DNA polymerase, 1 mgo fD NA, and HPLC water,i nafinal volume of 20 mL; and with the following routine: 95 8C/3 min, 30 cycles of 95 8C/30 s, 55.5 8C/45 s, 72 8C/30 s, and 72 8C/7 min. Finally,t he amplification products were subjected to electrophoresis on a2%a garose gel for 90 min at 90 V, containing 1:10 000 GelRed nucleic acid gel stain.
ELISA:S erum samples were obtained 2days after treatment, 1day before IS and on the day of necropsy for the mice treated in acute phase, and 2days after treatment and on the day of necropsy (sera post-IS) for the mice treated in the chronic phase. To obtain serum, blood was incubated in ag lass tube for 2h at 37 8Ct o allow clotting and then 16 ha t48Cf or retraction of the clot. The serum was collected and centrifuged at 2700 g for 20 min at 4 8C. The serum was used for ELISA and biochemical analysis as explained later in this paper.SOD excreted (SODe) from the parasites, extracted and purified as subsequently described, was used as the antigen fraction. Circulating antibodies in serum against T. cruzi Arequipa strain were qualitatively and quantitatively evaluated by ELISA. The serum from whole blood was diluted 1:80 in PBS, and all serum samples were analyzed in triplicate in polystyrene 96-well microtiter plates. The absorbance was read at 492 nm using am icroplate reader (Sunrise, TECAN). Mean and standard deviations of the optical densities of the negative control sera were used to calculate the cut-off value (mean plus three times the standard deviation). [47] Toxicity tests by biochemical analysis:S erum samples were obtained at 2days after treatment and on the day of necropsy (sera post-IS) both for mice treated in the acute and chronic phases. These sera were sent to the Biochemical Service of the University of Granada, where as eries of parameters were measured using commercial kits from Cromakit with the BS-200 Chemistry Analyzer Shenzhen Mindray (Bio-medical Electronics Co.,L TD). Mean values and standard deviations were calculated using the levels obtained for different populations of sera (n = 6, n = 3), and the confidence interval for the mean normal populations were also c calculated using the levels obtained for different populations of sera (n = 6, n = 3), and the confidence interval for the mean normal populations were also calculated based on ac onfidence level of 95 %[ 100 (1Àa) = 100 (1À0.05)].F igure 12 shows the timeline for all in vivo experiments in acute and chronic phases.
Studiesoft he mechanism of action
Metabolite excretion: T. cruzi Arequipa strain was grown and collected in the epimastigote form at 28 8C [59] in the exponential growth phase by centrifugation at 400 g for 10 min. The compounds to be tested were dissolved as mentioned above. The assays were performed in cell culture flasks (surface area, 25 cm 2 ) at 5 10 5 parasites per mL and after the addition of the compounds at IC 25 concentrations at 28 8C. Non-treated parasites were also included. After a7 2hincubation, treated and non-treated parasites were centrifuged at 800 g for 10 min to collect the supernatants to determine the excreted metabolites by 1 HNMR.
Chemical shifts were expressed in ppm using sodium 2,2-dimethyl-2-silapentane-5-sulfonate as the reference signal. The 1 HNMR spectra were acquired with aV ARIAN DIRECT DRIVE 400 MHz Bruker spectrometer with an AutoX probe using D 2 O. The assignments of metabolites were based on their 1 HNMR spectra. The chemical shifts used to identify the respective metabolites were consistent with those described previously by our group [65] and with the human metabolome database. The spectral region of 1.0-5.5 ppm was bucketed into af requency window of 0.1 ppm. The peak (2.6 ppm) corresponding to DMSO was removed before binning, and the regions corresponding to water (4.5-5.5 ppm) and glucose (3.4-3.8 ppm) were excluded during binning to avoid artefacts due to pre-saturation. The aromatic region was excluded because the signal-to-noise ratio in this region was poorer than in the aliphatic region. The resulting integrals were normalized to the working region (1.0-3.4) ppm of the spectrum to correct for inter-sample differences in dilution. The binning and normalizations were achieved using Mestrenova 9.0 software. The matrix obtained in Mes- Rho 123 and AO assays: T. cruzi Arequipa strain was grown and collected as epimastigote forms at 28 8C [59] in the exponential growth phase by centrifugation at 400 g for 10 min. The compounds to be tested were dissolved as mentioned above. The assays were performed in cell culture flasks (surface area, 25 cm 2 ) at 5 10 5 parasites per mL, and after the addition of the compounds at IC 25 concentration at 28 8C. Untreated parasites were also included. After a7 2hincubation, treated and untreated parasites were collected by centrifugation at 400 g for 10 min, and the pellets of parasites were washed three times with PBS. Subsequently,t he parasites were resuspended in 0.5 mL PBS with 10 mgmL À1 Rho 123 (Sigma-Aldrich) or 10 mgmL À1 AO (Sigma-Aldrich) for 20 min. [66] Finally,t he samples were washed twice with ice-cold PBS, dispersed in 1mLo fP BS and immediately analyzed by flow cytometry (Becton Dickinson FACSAria III). The data were captured and analyzed using BD FACSDiva v8.01 software (Becton Dickinson Biosciences, 2350 Qume Drive, San Jose, CA, USA). The fluorescence intensities for Rho 123 (mitochondrial membrane potential) and AO (DNA and RNA) were quantified based on the forward (FSC) and side (SSC) scatter,for which at otal of 10 000 events were acquired in the previously established region corresponding to T. cruzi epimastigotes. [67] Alterations in the fluorescence intensities of AO (APC-A) or Rho 123 (FITC-A) were quantified by the index of variation (IV) obtained using the equation (TM-CM)/CM, where TM is the median fluorescence for treated parasites and CM is the median fluorescence for non-treated parasites (control). [66] Extraction/purification of the SODe and SOD inhibition studies: T. cruzi Arequipa strain was grown as the epimastigote form at 28 8Ci nR PMI (Gibco)w ith 10 %( v/v)f etal bovine serum (heat-inactivated), 0.5 %( w/v)t rypticase (BBL) and 0.03 m hemin [55] in the exponential growth phase. The parasites were collected by centrifugation at 400 g for 10 min, and the pellet was resuspended at 5 10 9 parasites per mL in the same medium without fetal bovine serum in cell culture flasks (surface area, 75 cm 2 ). After a2 8hincubation at 28 8C, the culture was centrifuged at 800 g for 10 min at 4 8C, and the supernatant was collected and filtered with 0.45 mm pore size filters. Protein was precipitated by addition of ammonium sulfate and centrifugation at 10 000 g for 20 min at 4 8Ct omaintain the 35-85 %p rotein fraction, which was re-dissolved in 2.5 mL of 20 mm potassium phosphate buffer (pH 7.8) containing 1mm EDTA. Finally,t his fraction was desalted by gel filtration using aS ephadex G-25 column, [68] and the protein concentration was determined using the Bradford method (Sigma Immunochemical, St. Louis, MO, USA) with bovine serum albumin as as tandard. [69] Fe-SODe and commercial CuZn-SOD (Sigma-Aldrich) activities were determined using the method described by Beyer and Fridovich. [43] 
